NUS Medicine and CHA University Collaborate to Harness AI in Unlocking Novel Solutions for Reversing Male Infertility Decline

In a groundbreaking collaboration between the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) and CHA University in Korea, researchers have unveiled significant advancements aimed at extending reproductive longevity, a breakthrough that could reshape the landscape of fertility medicine amidst shifting demographic trends across Asia. Presented at the inaugural NUS-CHA Reproductive Medicine Symposium, these scientific achievements tackle two of the most pressing challenges in reproductive health: male infertility diagnostics and reversing age-related fertility decline.

Asia faces an unprecedented demographic shift characterized by rapidly declining fertility rates and rising reproductive health challenges. Male infertility rates in East and South Asia stand among the highest globally, contributing disproportionately to the worldwide infertility burden. As an increasing number of couples elect to have children later in life, the biological constraints imposed by aging exacerbate these reproductive hurdles. Despite remarkable progress in assisted reproductive technologies (ART), significant diagnostic and therapeutic gaps persist, particularly in addressing male infertility and age-associated deterioration in egg and embryo quality.

Harnessing the power of artificial intelligence (AI) combined with vast clinical datasets, researchers led by Adjunct Assistant Professor Huang Zhongwei from the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality (ACRLE), alongside Associate Professor Lee Jae Ho from CHA University, are pioneering new methods to revolutionize male infertility diagnostics. Male infertility affects nearly half of the millions of couples struggling with conception both regionally and worldwide, yet it remains one of the most under-recognized and under-treated facets of reproductive medicine. By applying sophisticated machine learning algorithms to multifaceted clinical data, the research aims to unearth hidden patterns within patient profiles that traditional analyses might overlook.

The integration of AI promises to transform clinical decision-making by providing actionable insights that enhance the accuracy and efficiency of male infertility diagnosis. This approach could facilitate early detection of subtle physiological anomalies or genetic markers associated with reduced fertility potential, thereby enabling personalized treatment strategies that maximize success rates. Such developments represent a paradigm shift, potentially reducing the time to diagnosis and improving prognostic outcomes for couples facing the emotional and financial toll of infertility.

Parallel to advances in male reproductive health, the team has made remarkable strides in combating age-related fertility decline—a formidable obstacle for women electing to conceive later in life. A significant barrier in reproductive medicine has been the progressive deterioration of egg and embryo quality with advancing maternal age, which no current hormone-based therapies have effectively reversed. Addressing this, the research identifies ferroptosis—a regulated form of cell death driven by iron accumulation and oxidative stress—as a key pathological mechanism responsible for mitochondrial dysfunction in aging embryos.

Published in the peer-reviewed journal Biomedicine & Pharmacotherapy, the study explores the therapeutic potential of MIT-001, a novel compound designed to ameliorate ferroptosis-induced mitochondrial damage. Using preclinical models of aged female mice, the researchers demonstrated that MIT-001 significantly improved embryo growth and blastocyst formation, effectively mitigating the self-destructive cellular processes that undermine embryo viability. This mitochondria-targeted intervention marks a promising departure from conventional hormone treatments, offering a precision medicine approach to rejuvenate reproductive cells at the molecular level.

Mitochondria, often characterized as cellular powerhouses, play a vital role in energy production and regulation of apoptosis. Their dysfunction in ageing reproductive cells results in poor embryo quality and impaired developmental potential. By specifically inhibiting ferroptosis, MIT-001 preserves mitochondrial integrity, thereby enhancing embryo resilience and promoting healthier embryogenesis. This strategy could herald a new era of fertility treatments focused on cellular rejuvenation, potentially extending reproductive windows and improving clinical outcomes for older women.

Beyond its direct implications for fertility, the findings bear broader significance for age-associated diseases and ageing biology. Ferroptosis and mitochondrial dysfunction are increasingly recognized as pivotal drivers of degenerative disorders across multiple tissues. Adjunct Assistant Professor Huang emphasizes that safeguarding cellular energy systems may offer novel avenues not only to preserve fertility but also to slow systemic ageing processes, enhancing overall healthspan and longevity.

The symposium itself, themed “Advances in Reproductive Medicine in Asia-Pacific,” gathered global thought leaders who explored cutting-edge innovations spanning microfluidic and AI-driven technologies in assisted reproduction, cellular aging in ovarian biology, 3D embryo imaging, and artificial endometrium models. Clinical automation in IVF laboratories and groundbreaking sperm selection methods were also highlighted, underscoring a holistic approach to tackling infertility through technological integration and molecular insights.

Together, these advances embody the ambitious vision of precision reproductive medicine—leveraging data-driven tools and targeted therapeutics to tailor interventions for individual patients. They hold transformative potential to alleviate the reproductive challenges posed by socioeconomic trends and biological constraints alike, offering hope to millions confronting infertility in Asia and beyond.

This dual-pronged research initiative underscores the critical need for continued investment in reproductive health innovations, particularly in regions disproportionately impacted by declining fertility rates and ageing populations. The integration of AI diagnostics for male infertility with mitochondria-targeted therapies in female reproductive ageing exemplifies a multidisciplinary strategy poised to redefine reproductive longevity.

As these pioneering studies move from preclinical validation towards clinical translation, the implications for reproductive medicine are profound. Couples grappling with infertility may soon access more effective diagnostic tools and treatments that overcome current limitations, extending their reproductive options and improving the likelihood of successful conception and healthy pregnancy outcomes.

In sum, the collaborative efforts between NUS Medicine and CHA University signify a transformative chapter in reproductive healthcare, merging technological prowess with molecular biology to confront the complex challenges of fertility preservation and restoration. This exciting frontier holds promise not only for reproductive medicine but also for advancing our broader understanding of ageing and cellular resilience.

News Publication Date: Not specified in the source content

Web References:

• https://pubmed.ncbi.nlm.nih.gov/40529032/
• https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/02/society-at-a-glance-asia-pacific-2025_e40bb2aa/24fa8f05-en.pdf
• https://www.ncbi.nlm.nih.gov/books/NBK562258/
• https://www.sciencedirect.com/science/article/pii/S0753332225005876?via%3Dihub

References:

• Huang, Z., Lee, J., et al. “MIT-001 ameliorates ferroptosis-induced mitochondrial dysfunction and enhances embryo quality in preimplantation embryos from aged female mice.” Biomedicine & Pharmacotherapy. DOI: 10.1016/j.biopha.2025.118393